The growth of Viagra and its effect on the pharmaceutical landscape presents a complex question for investors. While the initial sales data were impressive, the exclusivity has ended, leading to a wave of off-brand alternatives that are chipping away at profit. Furthermore, the market is facing difficulties related to aging trends and changing heal